Smith+Nephew to Report Q1 2024 Results on May 1

TL;DR

SN dropping Q1 earnings May 1st, get ready.

AI Summary

Smith+Nephew plc announced on April 23, 2024, that it will release its trading report for the first quarter ended March 30, 2024, on Wednesday, May 1, 2024, at 7:00 am GMT. The report will cover the company's financial performance for the initial three months of 2024.

Why It Matters

Investors will gain insight into Smith+Nephew's financial health and operational performance in the first quarter of 2024, which can influence investment decisions.

Risk Assessment

Risk Level: low — This filing is a routine announcement of a future earnings report date, with no new financial data or significant events disclosed.

Key Players & Entities

• Smith+Nephew plc (company) — Registrant
• May 1, 2024 (date) — Date of Q1 2024 trading report release
• March 30, 2024 (date) — End of Q1 2024 period
• 7:00 am GMT (time) — Time of Q1 2024 trading report release

FAQ

Key Financial Figures

• $5.5 billion — ountries, and generated annual sales of $5.5 billion in 2023. Smith+Nephew is a constituent

Filing Documents

• a6835l.htm (6-K) — 24KB
• 0001654954-24-004893.txt ( ) — 26KB

Forward-looking Statements

Forward-looking Statements   This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading profit margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements.

Forward-looking statements involve known and unknown risks,

Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: conflicts in Europe and the Middle East, economic and financial conditions in the markets we serve, especially those affecting healthcare providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal and financial compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and disposals, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; relationships with healthcare professionals; reliance on information technology and cybersecurity; disruptions due to natural disasters, weather and climate change related events; changes in customer and other stakeholder sustainability expectations; changes in taxation regulations; effects of foreign exchange volatility; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, which is available on the SEC's website at ww

SIGNATURES

SIGNATURES   Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.             Smith & Nephew plc     (Registrant)             Date: April 23, 2024 By: /s/ Helen Barraclough     Helen Barraclough     Company Secretary

View Full Filing

View this 6-K filing on SEC EDGAR